Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal
Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share
PE investor Nordic Capital has offered to buy Advanz Pharma, valuing the company at $846 million as part of a move to invest in accelerating the company’s pipeline of innovative specialty pharma products.
Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share and can also elect a non-cash alternative offer to receive unlisted shares in Cidron Aida for each Advanz Pharma share.
(Edits by EP News Bureau)
- Advertisement -